GE Healthcare Launches Xuri IL-2 Growth Factor
GE Healthcare launches the Xuri IL-2 for the activation and expansion of T-lymphocytes.
GE Healthcare introduces the Xuri IL-2, a cell therapy ancillary product for the ex-vivo cultivation of T-lymphocytes. Xuri IL-2’s level of biological activity removes the need for revalidation of each lot and improves reproducibility, thereby minimizing process development time and improving scale out capacity.
Xuri IL-2 features low endotoxin levels (<0.025 EU/µg) and is supplied with instructions for expansion in static culture and with the Xuri Cell Expansion Systems W5 and W25. In addition, the IL-2 is available for preclinical use, an alternative for the cultivation of T-lymphocytes in proof-of-principle and basic research experiments. The close equivalence between IL-2 and Xuri IL-2 simplifies the transition from research to process development for cell therapy manufacturing with minimized optimization time while supporting regulatory compliance.
Source: GE Healthcare
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
